APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

November 10, 2022

Study Completion Date

February 21, 2023

Conditions
Esophageal CancerGastroEsophageal Cancer
Interventions
DRUG

APX005M

APX005M IV infusion

RADIATION

Radiation Therapy

Radiation therapy, total dose 5040cGy in 180cGy fractions

DRUG

Paclitaxel

Paclitaxel IV infusion

DRUG

Carboplatin

Carboplatin IV infusion

PROCEDURE

Surgical resection of tumor

Surgical removal of the tumor will occur between weeks 10-17

Trial Locations (10)

10016

New York University, New York

27157

Wake Forest School of Medicine, Winston-Salem

45219

University of Cincinnati Medical Center, Cincinnati

77380

Renovatio Clinical, The Woodlands

85719

University of Arizona, Tucson

91010

City of Hope Comprehensive Cancer Center, Duarte

94143

University of California, San Francisco, San Francisco

98109

University of Washington, Seattle

20007-2113

MedStar Georgetown University Hospital (MGUH), Washington D.C.

27599-7305

The University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

Apexigen America, Inc.

INDUSTRY

NCT03165994 - APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | Biotech Hunter | Biotech Hunter